E
EDIT
Editas Medicine Inc
2.350
-0.090-3.69%After Hours: 2.350 0.000 0.00%19:30 10/16 EDT
OPEN/PREV CLOSE2.440/2.440
TODAY RANGE2.330-2.470
VOL1.55M
MARKET CAP360.91M
52 WEEK RANGE1.660-4.330
AVG VOL (3M)2.53M
% TURNOVER0.84%
TURNOVER--
P/E (TTM)-3.1565
% RANGE5.74%
EPS(TTM)-0.7445
P/E(FORWARD)-2.9987
P/B3.427
BVPS0.6857
DIVIDEND--
P/S5.68
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP360.26M
SHARES OUTSTANDING153.58M
NEXT EARNINGS11/09-11/13
FREE FLOAT153.30M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
NASDAQ·10/08 23:15
Wells Fargo Upgrades Editas Medicine to Overweight from Equal-Weight
Seeking Alpha·10/08 15:58
Editas upgraded at Wells Fargo as Australia approves gene editing trial
Dow Jones·10/08 15:35
Editas Medicine Price Target Raised to $6.00/Share From $4.00 by Wells Fargo
Dow Jones·10/08 15:35
Editas Medicine Raised to Overweight From Equal-Weight by Wells Fargo
Benzinga·10/08 15:25
Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6
TipRanks·10/08 15:15
Wells Fargo upgrades Editas Medicine after EDIT-401 study gets green light
TipRanks·10/08 15:10
Editas Medicine upgraded to Overweight from Equal Weight at Wells Fargo
TipRanks·10/08 11:28
Editas wins approval to launch EDIT-401 Strive trial
TipRanks·10/08 11:06
Editas Medicine receives approval to initiate clinical trial of EDIT-401
Seeking Alpha·09/29 11:30
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
TipRanks·09/26 09:01
Editas, Sagimet, Dropbox, Arcturus, Quanta Trending With Analysts
Seeking Alpha·09/25 20:00
Prime: A Buy Due To BLA Filing H1 '27 And Continued PM647 Advancement